US Edition
Published • loading... • Updated
Health Canada approves first generic version of Novo Nordisk's Ozempic
Health Canada said the generic semaglutide meets safety, efficacy and quality standards and may lower costs for patients and the healthcare system.
- On Tuesday, Health Canada approved the first generic version of Novo Nordisk's blockbuster diabetes drug Ozempic, manufactured by Indian drugmaker Dr. Reddy's Laboratories.
- Health Canada stated that generic semaglutide drugs are "pharmaceutically equivalent" to the brand-name version, with many generics 45 to 90 percent cheaper than brand-name medications in Canada.
- The regulator approved the submission after a thorough review found the drug meets safety, efficacy, and quality standards for once-weekly treatment of adult patients with Type 2 diabetes.
- Health Canada is currently reviewing eight other applications for generic semaglutide and expects to make additional decisions in the coming weeks and months.
- Officials expect the availability of generic drugs to have "a positive impact in Canada, including potential cost savings for patients and the healthcare system," the department said.
Insights by Ground AI
Podcasts & Opinions
54 Articles
54 Articles
New Hamburg independentReposted by 
OurWindsor.ca
OurWindsor.caHealth Canada approves first Ozempic generic alternative. Here’s what you need to know
Widespread use of generic GLP-1 medications could help Ontario residents save money and lose weight while forcing the food industry to adapt. Health authorities warm the drugs may not be suitable for everyone due to potential short and long-term health effects.
·New Hamburg, Canada
Read Full Article
Many generic drugs cost between 45% and 90% less than their brand equivalents.
·Montreal, Canada
Read Full Article
Le Journal de MontrealReposted by 
24heures.ca
24heures.caHealth Canada announced on Tuesday the authorization of a first generic Ozempic in the country.
·Montreal, Canada
Read Full Article
Coverage Details
Total News Sources54
Leaning Left27Leaning Right3Center8Last UpdatedBias Distribution71% Left
Bias Distribution
- 71% of the sources lean Left
71% Left
L 71%
C 21%
Factuality
To view factuality data please Upgrade to Premium
